Earnings call transcript: Imricor posts tiny Q2 2026 revenue as U.S. launch begins
Imricor Medical Systems reported a slight decline in its second-quarter revenue, totaling $61,000, down about 6% from the same period last year. The company also posted an adjusted net loss of AUD 7.0 million, reflecting a significant widening from AUD 5.1 million in the prior year. This loss is attributed to higher operating expenses related to marketing, staffing, and production capacity expansion.
Despite the small revenue figure, the company's U.S. launch of its MR-guided cardiac intervention platform marks a significant step forward. Imricor has received four FDA clearances and seen progress in clinical trials, but the company remains in the early stages of commercialization. Management expressed optimism about the second half of 2026, anticipating a revenue inflection driven by U.S. NorthStar sales and European site expansion.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
